简介:Glatiramer醋酸盐(GA)是过去常对待多重硬化的immunomodulatory肽药。它的处理效果被扩展了到象uveoretinitis,煽动性的肠疾病,接枝拒绝和肝的纤维变性那样的另外的自体免疫的条件。这里,我们报导GA在在cyclophosphamide(CY)改变糖尿病的临床的功课是有效的加强的非肥胖的糖尿病患者(CY点头)老鼠。有显著地减少的GA的治疗在老鼠和改善insulitis的糖尿病的率,它与增加的CD4+CD25+Foxp3+T房间反应与一致在对待老鼠。GA处理导致了抄写因素Foxp3的增加的表示并且在vivo并且在vitro提高了interleukin-4(IL-4)的生产。Foxp3的起来规定上的GA的效果通过IL-4部分被调停,是明显的。IL-4被发现维持Foxp3表示和CD4+CD25+规章的T房间(Tregs)的规章的功能。这研究提供GA通过Tregs的正式就职为类型1糖尿病有处理潜力,那增加的IL-4生产为提高的Treg在GA处理的功能部分负责的新证据。
简介:CellsregulatephospholipaseD(PLD)activityinresponsetonumerousextracellularsignals.Here,weinvestigatedtheinvolvementofPLDactivityintransforminggrowthfactor-β(TGF-β1)-mediatedgrowthinhibitionofepithelialcells.TGF-β1)-mediatedgrowthinhibitionofepithelialcells.TGF-β1inhibitsthegrowthofMDCK,Mv1Lu,andA-549cells.Inthepresenceof0.4%butanol,TGF-β1inducesanincreaseintheformationofphosphatidylbutanol,auniqueproductcatalyzedbyPLD.TGF-β1alsoinducesanincreaseinphosphatidicacid(PA)levelinA-549andMDCKcells.TGF-β1inducesanincreaseinthelevelsofDAGlabeledwith[^3H]-myristicacidinA-549andMDCKcellsbutnotinMv1Lucells.NoincreaseofDAGwasobservedincellsprelabeledwith[^3H]-arachidonicacid.ThedatapresentedsuggestthatPLDactivationisinvolvedintheTGF-β1-inducedcellgrowthinhibition.
简介:现在的学习试图定义postsynaptic的角色在多巴胺(DA)的规定的密度(PSD)-95受体功能。我们发现PSD-95身体上在co-transfectedHEK-293房间与D1或D2DA受体联系。DA受体的刺激以一种时间依赖者方式改变了在D1受体和PSD-95之间的协会。功能的试金显示PSD-95合作表示没影响D1刺激受体的营地生产,Gs蛋白质激活或受体不敏感性。然而,PSD-95由支持受体再循环加速了使内在化的膜受体的恢复,因此导致使内在化的D1受体的提高的促进感受性。我们的结果提供新奇机制因为调整再循环那的DA受体可以在postsynapticDA功能的调整和synapticneuroplasticity起一个重要作用。
简介:Amurinemacrophage-likecelllineJ774,acquired,inresponsetoLPS,anabilitytokilltumornecrosisfactor(TNF)-insensitivetargetP815mastocytomacellswhereasanothercellline,P388D1didnot,LPStriggeredsignalingmechanismsbetweenthetwocelllineswerecomparedwithanaimtoinquireaboutthepossiblenatureoftheabove-mentioneddifference,TheresultswhowedthattwocelllinesrespondtoLPS-treatmentbyparallelactivationofbothphospholipasesCandA2(PLCandPLA2)toapproximatelythesameextent.ThemaximumresponseoftothenzymesofJ774cellswasnotedwithin10minthetreatmentwhereasthatofP388D1cellsrequiredmorethan20min,TheotherpropertiesofLPS-responsiveenzymesstudiedweresimilarbetweentwocelllines,includingActivationofPLCandPLA2andPKCinmacrophagesbyLPS.Ca2+augmentationofenzymeactivation,participationofguaninenucleotidebinding(G)proteinsintheinitialactivationpreocesses,andinhibitionofenzymeactivationbythepriortreatmentofcellswithcholeraorpertussistoxinsetc.Moreover,LPS-triggeredactivationofPLCandPLA2wasfoundtobefollowedbytheincreaseofPKCactivitiesinbothcelllines.Inspiteofthesesimilarities.J774cellspossessedbothbasicandacidicformsofPKCactivities,whileP388D1cellsownedonlyPKCofbasicform,Nevertheless,thequestionwhyJ774cellsbutnotP388D1cells,canacquirethetumoricidalactivity,aganistP815,cellsfollowingLPStreatmentrematinstobeanswered.
简介:Amurinemacrophage-likecellline,J774,acquried,inresponsetoLPS,anabilitytokilltumornecrosisfactor(TNF)-insensitivetargetP815mastocytomacells,whereasanothercellline,P388D1,didnot.LPS-triggeredsignalingmechanismsbetweenthetwocelllineswerecomparedwithanaimtoinquireaboutthepossiblenatureoftheabove-mentioneddifference.TheresultsshowedthattwocelllinesrespondtoLPS-treatmentbyparallelactivationofbothphospholipasesCandA2(PLCandPLA2)toapproximatelythesameextent.ThemaximumresponseofbothenzymesofJ774cellswasnotedwithin10minofthetreatment,whereasthatofP388D1cellsrequiredmorethan20min.TheotherpropertiesofLPS-responsiveenzymesstudiedweresimilarbetweentwocelllines,ineludingActivationofPLCandPLA2andPKCinmacrophagesbyLPSCa2+augmentationofenzymeactivation,participationofguaninenucleotidebinding(G)proteinsintheinitialactivationprocesses,andinhibitionofenzymeactivationbythepriortreatmentofcellswithcholeraorpartussistoxinsetc.Moreover,LPS-triggeredactivationofPLCandPLA2wasfoundtobefollowedbytheincreaseofPKCactivitiesinbothcelllines.Inspiteofthesesimilarities,J774cellspossessedbothbasicandacidicformsofPKCactivities,whileP388D1cellsownedonlyPKCofbasicform.Nevertheless,thequestionwhyJ774cells,butnotP388D1cells,canacquirethetumoricidalactiyity,aganistP815cellsfollowingLPS-treatmentremainstobeanswered.